a pharmaceutical treatment for canine mast cell tumours

STELFONTA® (tigilanol tiglate)

Tigilanol tiglate, branded as STELFONTA®*, is approved and marketed as a veterinary pharmaceutical for treatment of non-metastatic, canine mast cell tumours1,2  in the United States of America, European Union, Switzerland, United Kingdom and Australia.

Visit website*

*This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.

  1. STELFONTA® (tigilanol tiglate injection) packaging insert (2020)
  2. European Medicines Agency. (2020).STELFONTA®.